Modified tuberculosis vaccine as therapy against bladder cancer

March 5, 2020

The Max Planck Insitute for Infection Biology is sharing news of interest to the Immunology Community.

Therapy with VPM1002 is effective in bladder cancer patients

The human immune system can recognize and eliminate not only germs but also cancer cells. This is why treatments with weakened germs can help the immune system it ist fight against cancer.

The Max Planck Insitute for Infection Biology has developed a vaccine against TB which is currently in phase III trial. Less known is that this vaccine is also tested for treatment of bladder cancer and it has now shown a remarkable outcome in a clinical trial in preventing cancer recurrence.

clinical trial no.: NCT02371447 (https://clinicaltrials.gov/ct2/show/NCT02371447)

More News

Visit the IUIS Booth at the IUIS 2025 Congress!

July 29, 2025

A message from IUIS President, Dr Miriam Merad

July 2, 2025

Congratulations to the Winners of the 2025 Day of Immunology Awards

June 30, 2025

Is there an IEI you want to see in the next IUIS IEI classification? Submit it to us now!

June 16, 2025Inborn Errors of Immunity Committee (IEI)

Meet the IUIS 2025 Rising Stars!

June 12, 2025Early Career Committee (ECC)

Teaching Sustainable Development Goals: Methods for Education

May 20, 2025Immunotherapy Committee (ITH), Education Committee (EDU)

Apply Now: Michelson Prizes – $150,000 Grants for Emerging Leaders in Immunology

May 13, 2025Early Career Committee (ECC)

Announcing the 2025 Excellence in Immunology Award Winner: Dr. Arlene Sharpe

May 5, 2025Gender Equity Committee (GEC)

IUIS Invites Bids to Host the 21st Congress of the International Union of Immunological Societies (IUIS2031)

April 29, 2025